Leerink Partners Raises price Target on Diplomat Pharmacy (DPLO) to $38 Following Mixed 2Q

August 10, 2016 7:07 AM EDT
Get Alerts DPLO Hot Sheet
Price: $14.06 --0%

Rating Summary:
    6 Buy, 7 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade DPLO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Leerink Partners reiterated an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and raised the price target to $38.00 (from $36.00), following the company's 2Q earnings report. DPLO reported total revenue of $1,089M, 3% below consensus of $1,118M. Adjusted EPS $0.23 was above the consensus estimates of $0.21.

Analyst David Larsen commented, "While DPLO continues to outgrow the specialty pharmacy market with organic growth of 28% y/y in 2Q, the quarter was a mixed bag as revenue missed on lower volumes but earnings were slightly ahead of expectations and guidance was reaffirmed. Consolidation opportunities remain plentiful for DPLO with management actively looking at regional specialty pharmacies and we expect acquisitions to continue to be a growth tailwind. We reduce our estimates on slightly lower volume and margin assumptions but maintain our OP rating, PT to $38 (from $36) and recommend buying on weakness."

For an analyst ratings summary and ratings history on Diplomat Pharmacy click here. For more ratings news on Diplomat Pharmacy click here.

Shares of Diplomat Pharmacy closed at $36.79 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities


Add Your Comment